Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

Reviewing test results with a patient with cancer.

Lung Cancer

Nearly 1 in 10 Cancer Patients May Not Receive Guideline-Concordant Care

Andrea S. Blevins Primeau, PhD, MBA

April 5, 2022

The highest rate of non-concordant care was seen in patients with cervical cancer.

Lung Cancer

Half of Cancer Patients Lost Neutralizing Antibodies 6 Months After COVID-19 Vaccination

Andrea S. Blevins Primeau, PhD, MBA

April 4, 2022

Roughly half of patients with hematologic cancers or solid tumors lost neutralizing antibody responses to SARS-CoV-2 variants of concern at 6 months after vaccination.

General Pulmonology

Poor Understanding of Prognosis Observed in Older Adults With Advanced Cancer

Andrea S. Blevins Primeau, PhD, MBA

March 8, 2022

Of the patients studied, 59% demonstrated poor prognostic understanding of curability.

Lung Cancer

Proton Pump Inhibitors May Reduce Efficacy of Atezolizumab

Andrea S. Blevins Primeau, PhD, MBA

March 2, 2022

The association between proton pump inhibitors and reduced efficacy of atezolizumab suggest “an urgent need” for evidence on how PPIs might impact other immune checkpoint inhibitors, according to researchers.

Lung Cancer

7 Factors Linked to COVID-19 Mortality in Patients With Thoracic Cancer

Andrea S. Blevins Primeau, PhD, MBA

February 11, 2022

ECOG performance status was most strongly associated with death.

Lung Cancer

Extending Dosing Interval May Not Impact Safety, Efficacy of ICIs in Lung Cancer

Andrea S. Blevins Primeau, PhD, MBA

January 12, 2022

Survival outcomes were similar for patients with an extended dosing interval and patients who received standard dosing.

General Medicine

HSCT After COVID-19 Appears Safe, but Most Patients Lose SARS-CoV-2 Antibodies

Andrea S. Blevins Primeau, PhD, MBA

November 11, 2021

All patients achieved engraftment, and none developed complications associated with COVID-19.

Lung Cancer

Mobocertinib May Meet Unmet Need in Non-Small Cell Lung Cancer

Andrea S. Blevins Primeau, PhD, MBA

October 29, 2021

In the platinum-pretreated cohort, the objective response rate was 28%.

The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerg

Lung Cancer

Floxacin Antibiotics May Augment Treatment of Lung and Bladder Cancers by Inhibiting RSK4

Andrea S. Blevins Primeau, PhD, MBA

August 3, 2021

RSK4-targeting floxacins could boost the efficacy of chemotherapy.

A liquid biopsy or simple blood test can reliably and swiftly genotype 2 key genes associated with a

Lung Cancer

Severe Lymphopenia Associated With Shorter PFS in Unresectable, Stage III NSCLC

Andrea S. Blevins Primeau, PhD, MBA

April 5, 2021

A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.

Next post in Lung Cancer